FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2289226269> ?p ?o ?g. }

• W2289226269 endingPage "e14559" @default.
• W2289226269 startingPage "e14559" @default.
• W2289226269 abstract "e14559 Background: The clinical efficacy of Bevacizumab (BEV) in advanced colorectal cancer (mCRC) could be related not only to its well-established effect on tumor neoangiogenesis but also to a counteraction of VEGF-mediated dendritic cell (DC) abnormalities. The addition of BEV to chemotherapy (CT) may improve the number and function of blood DCs in cancer pts. We have focused on the correlation between this effect and the clinical efficacy of a BEV-based, 1 st -line treatment for mCRC. Methods: Starting from January 2007 we performed a flow cytometric analysis of PB lymphocytes and DC subsets in 53 mCRC pts who had not received prior CT for metastatic disease or for whom 6 months had elapsed since adjuvant CT (M/F: 31/22, median age: 59yrs; range 32–75; ECOG PS <2), before and every 3 courses of a BEV+CT (5-FU± CPT11± Oxaliplatin) program. Biological data of the 42 evaluable pts that received all the planned treatment were correlated to both tumor response (OR) and progression free survival (PFS). Results: During treatment, DCs and their subsets showed a progressive, significant increase in absolute number, with respect to baseline, both in responder (CR,PR,SD) (67%) and in non responder pts. This effect on the DC profile was evidenced in responder pts up to 4 weeks since the last treatment course. After therapy completion, pts with PFS > 15 months (58%) showed DC and DC1 absolute number significantly higher with respect to pts with shorter PFS (p< .02). Conclusions: The recovery of blood DCs induced by 1 st - line, BEV-based therapy in mCRC pts indicates a potential additional anticancer mechanism of this drug. The improvement of DC number does not influence OR but correlates with longer PFS. This suggests that BEV can influence tumor regrowth by contributing to overcome the impairement of the host immune surveillance induced by VEGF. No significant financial relationships to disclose." @default.
• W2289226269 created "2016-06-24" @default.
• W2289226269 creator A5012034272 @default.
• W2289226269 creator A5016560689 @default.
• W2289226269 creator A5029031145 @default.
• W2289226269 creator A5033692691 @default.
• W2289226269 creator A5054413273 @default.
• W2289226269 creator A5065122298 @default.
• W2289226269 creator A5066742157 @default.
• W2289226269 creator A5070385651 @default.
• W2289226269 creator A5077680828 @default.
• W2289226269 creator A5089288192 @default.
• W2289226269 date "2009-05-20" @default.
• W2289226269 modified "2023-09-27" @default.
• W2289226269 title "Correlation of immunological effects of anti-VEGF therapy with progression-free survival of advanced colorectal cancer patients" @default.
• W2289226269 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.e14559" @default.
• W2289226269 hasPublicationYear "2009" @default.
• W2289226269 type Work @default.
• W2289226269 sameAs 2289226269 @default.
• W2289226269 citedByCount "0" @default.
• W2289226269 crossrefType "journal-article" @default.
• W2289226269 hasAuthorship W2289226269A5012034272 @default.
• W2289226269 hasAuthorship W2289226269A5016560689 @default.
• W2289226269 hasAuthorship W2289226269A5029031145 @default.
• W2289226269 hasAuthorship W2289226269A5033692691 @default.
• W2289226269 hasAuthorship W2289226269A5054413273 @default.
• W2289226269 hasAuthorship W2289226269A5065122298 @default.
• W2289226269 hasAuthorship W2289226269A5066742157 @default.
• W2289226269 hasAuthorship W2289226269A5070385651 @default.
• W2289226269 hasAuthorship W2289226269A5077680828 @default.
• W2289226269 hasAuthorship W2289226269A5089288192 @default.
• W2289226269 hasConcept C121608353 @default.
• W2289226269 hasConcept C126322002 @default.
• W2289226269 hasConcept C143998085 @default.
• W2289226269 hasConcept C2776694085 @default.
• W2289226269 hasConcept C2777802072 @default.
• W2289226269 hasConcept C2777863537 @default.
• W2289226269 hasConcept C2780739268 @default.
• W2289226269 hasConcept C2780962732 @default.
• W2289226269 hasConcept C526805850 @default.
• W2289226269 hasConcept C71924100 @default.
• W2289226269 hasConcept C90924648 @default.
• W2289226269 hasConceptScore W2289226269C121608353 @default.
• W2289226269 hasConceptScore W2289226269C126322002 @default.
• W2289226269 hasConceptScore W2289226269C143998085 @default.
• W2289226269 hasConceptScore W2289226269C2776694085 @default.
• W2289226269 hasConceptScore W2289226269C2777802072 @default.
• W2289226269 hasConceptScore W2289226269C2777863537 @default.
• W2289226269 hasConceptScore W2289226269C2780739268 @default.
• W2289226269 hasConceptScore W2289226269C2780962732 @default.
• W2289226269 hasConceptScore W2289226269C526805850 @default.
• W2289226269 hasConceptScore W2289226269C71924100 @default.
• W2289226269 hasConceptScore W2289226269C90924648 @default.
• W2289226269 hasIssue "15_suppl" @default.
• W2289226269 hasLocation W22892262691 @default.
• W2289226269 hasOpenAccess W2289226269 @default.
• W2289226269 hasPrimaryLocation W22892262691 @default.
• W2289226269 hasRelatedWork W1963973664 @default.
• W2289226269 hasRelatedWork W1997133872 @default.
• W2289226269 hasRelatedWork W2037428781 @default.
• W2289226269 hasRelatedWork W2050348440 @default.
• W2289226269 hasRelatedWork W2051540233 @default.
• W2289226269 hasRelatedWork W2098707609 @default.
• W2289226269 hasRelatedWork W2145753255 @default.
• W2289226269 hasRelatedWork W2316610093 @default.
• W2289226269 hasRelatedWork W2545945608 @default.
• W2289226269 hasRelatedWork W1967062665 @default.
• W2289226269 hasVolume "27" @default.
• W2289226269 isParatext "false" @default.
• W2289226269 isRetracted "false" @default.
• W2289226269 magId "2289226269" @default.
• W2289226269 workType "article" @default.